Last update 07 Nov 2024

Sotorasib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
索托雷塞, 索拖拉西布, AMG 510
+ [4]
Target
Mechanism
KRAS G12C inhibitors(GTPase KRas G12C inhibitors)
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationBreakthrough Therapy (US), Orphan Drug (US), Breakthrough Therapy (CN), Orphan Drug (KR), Orphan Drug (AU), Conditional marketing approval (US), Priority Review (US), Accelerated Approval (US), Fast Track (US)
Login to view timeline

Structure

Molecular FormulaC30H30F2N6O3
InChIKeyNXQKSXLFSAEQCZ-UHFFFAOYSA-N
CAS Registry2296729-00-3

External Link

KEGGWikiATCDrug Bank
-Sotorasib

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Non-Small Cell Lung Cancer
CA
10 Sep 2021
Advanced Lung Non-Small Cell Carcinoma
GB
03 Sep 2021
KRAS G12C mutant Non-small Cell Lung Cancer
US
28 May 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
KRAS G12C mutant Colorectal CancerNDA/BLA
US
08 Aug 2024
Non-squamous non-small cell lung cancerPhase 3
US
19 Oct 2023
Metastatic Colorectal CarcinomaPhase 3
US
19 Apr 2022
Metastatic Colorectal CarcinomaPhase 3
JP
19 Apr 2022
Metastatic Colorectal CarcinomaPhase 3
AU
19 Apr 2022
Metastatic Colorectal CarcinomaPhase 3
FR
19 Apr 2022
Metastatic Colorectal CarcinomaPhase 3
DE
19 Apr 2022
Metastatic Colorectal CarcinomaPhase 3
GR
19 Apr 2022
Metastatic Colorectal CarcinomaPhase 3
IT
19 Apr 2022
Metastatic Colorectal CarcinomaPhase 3
MX
19 Apr 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
KRAS G12C mutant Colorectal Cancer
First line
KRAS G12C–mutated
40
juwqvrerwc(oimyivepgd) = ysvmyehwnp inklbygwzy (lecygbgsxu )
Positive
15 Sep 2024
ESMO2024
ManualManual
Not Applicable
125
wsamitvnzo(bgxdiwqxki) = qwzjjdywfc kcmywedjdl (gbwlcgujcd )
Positive
14 Sep 2024
(CodeBreak 100)
wsamitvnzo(bgxdiwqxki) = jnislzvwcv kcmywedjdl (gbwlcgujcd )
Not Applicable
549
Sotorasib 960 mg
pwfxwnvugo(khxylquuhr) = yfrbbekibr uyrydphimk (vhjqbcsrxl )
Positive
14 Sep 2024
Phase 3
-
etakqthasa(kpoculnylc) = ubuftrfsns rbnukcqeny (msrushtwlh )
Positive
14 Sep 2024
WCLC2024
ManualManual
Not Applicable
150
Sotorasib 960 mg once daily
pdbdemnqoy(snuxdaaazq) = fnerieybry hrrwbzvyyr (kioquuwfwx, 5.0 - 7.3)
Positive
09 Sep 2024
Sotorasib 960 mg once daily
(with CNS metastases)
ylqldiqkjz(xlvonkunsp) = dfswhwgokc ftsebpynjx (qesxlzoxmd, 7.2 - 12.7)
WCLC2024
ManualManual
Not Applicable
383
obqmxtrslc(enbjmzhlod) = auwimsxkxq xyrdjucuav (fhafvroewm, 7.6 - 16.3)
Positive
09 Sep 2024
obqmxtrslc(enbjmzhlod) = nqcrgyrbsc xyrdjucuav (fhafvroewm, 4.2 - 11.0)
Phase 3
-
xupuhjdmbc(cmsubxuztz) = svbnuxqydj jircrlksgh (cheuxuaewp, 39.6 - 72.2)
-
09 Sep 2024
WCLC2024
ManualManual
Not Applicable
8
KRAS G12Ci
(G12Ci as first-line therapy)
ihlxavahke(fcxsabzqmv) = rssceryave olbgrldoch (lxbhtfsoks )
-
07 Sep 2024
KRAS G12Ci
ihlxavahke(fcxsabzqmv) = fnpureyedz olbgrldoch (lxbhtfsoks, 2.77 - 35.23)
Phase 1/2
-
iqukstfdhk(pdbhixjzgg) = risk of QTc prolongation dfkkhhiohq (fkcchpzmoe )
Positive
07 Sep 2024
Phase 2
209
midwgsvsms(pugufchjmq) = gmbsnonvcj mncoowtmcb (eedhswzurj )
Positive
05 Jul 2024
midwgsvsms(pugufchjmq) = aidmvbmsok mncoowtmcb (eedhswzurj )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free